Adimab
The power of integration.

May 28, 2008
Press Release

Adimab, Inc expands Scientific Advisory Board with Dr. Sachdev Sidhu

Lebanon, NH – May 28, 2008 – Adimab, Inc. today announces the addition of Dr. Sachdev Sidhu to its scientific advisory board. Dr. Sidhu recently joined the faculty in the Banting and Best Department of Medical Research at the University of Toronto. Professor Sidhu returns to academia after a distinguished career at Genentech where he led the development of the company's phage display technology.

"At Genentech Dr. Sidhu made significant contributions and established himself as a recognized thought leader in the area of semi-synthetic antibody library design," said Dr. Tillman Gerngross, Adimab Chief Executive Officer and Co-founder. "He brings a wealth of experience in commercial antibody discovery and we are excited to have him join the board."

Dr. Dane Wittrup, the Chairman of Adimab's Scientific Advisory Board, added, "Dr. Sidhu is intimately familiar with conventional antibody discovery technologies and has been on the cutting edge of the field for many years. In particular, he has made major contributions to understanding the functional importance of the amino acid composition of antibody binding sites. His insight will be highly valued."

"I'm very excited to join Adimab's scientific advisory board," remarked Dr. Sidhu, "the company is pushing the envelope on what is possible in therapeutic antibody engineering, and I look forward to working with the team."

Dr. Sidhu joins the current scientific advisory board consisting of: Prof. Stanley Fields, a Howard Hughes Medical Investigator at the University of Washington, Prof. Jim Marks of the National Academy of Medicine and the University of California, San Francisco, Prof. Bruce Tidor of the Massachusetts Institute of Technology, and Dr. Dane Wittrup, Chairman and Co-founder of Adimab and Professor of Engineering at the Massachusetts Institute of Technology.

About Adimab, Inc.

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology. For more information, visit http://www.adimab.com.

###

Contact
Errik B. Anderson
VP Operations & Finance
Adimab, Inc.
(603) 727-7107
errik.anderson@adimab.com